Japan Oncolytic Viral Therapy Market 2025-2030: Breakthrough Advancements in Targeted Cancer Therapy | Key Leaders: Daiichi Sankyo Co., Ltd., Amgen Inc., Lokon Pharma AB

Tokyo, Japan, DataM Intelligence: The Japan Oncolytic Viral Therapy Market was valued at approximately USD 200 million in 2022 and is projected to reach USD 900 million by 2030, growing at a CAGR of about 19.5% from 2024 onwards.

This growth is driven by strong government support, advanced gene therapy and virology research, and regulatory approvals for oncolytic virus therapies, particularly for difficult-to-treat cancers like malignant glioma. Rising cancer incidence, increasing clinical trials, and focus on combination therapies with immune checkpoint inhibitors further propel market expansion. Japan's healthcare infrastructure and emphasis on innovation in immuno-oncology also contribute significantly to this market growth.

Japan: Key Industry Developments

✅ October 2025: Japan's oncolytic viral therapy market saw advancements with increasing clinical trials focusing on genetically modified viruses for targeted cancer treatment, notably in pancreatic and gastric cancers, supported by robust government funding and collaboration between pharmaceutical firms and research institutes.

✅ April 2025: The Ministry of Health, Labour and Welfare (MHLW) continued streamlining regulatory pathways with its special approval system for regenerative medicines, enhancing market access for oncolytic viral therapies like Daiichi Sankyo's DELYTACT, Japan's first approved oncolytic virus therapy for recurrent glioblastoma.

✅ Early 2025: Expansion of public-private partnerships and investments accelerated, fostering innovation in viral engineering to improve therapeutic efficacy and safety, with growing focus on personalized medicine and combination immunotherapies to enhance cancer patient outcomes.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/oncolytic-viral-therapy-market?ram

Mergers and Acquisitions (2025):

✅ In February 2025, UroGen Pharma expanded its oncology pipeline by acquiring IconOVir's oncolytic virus assets, including the next-generation candidate ICVB-1042, enhancing its focus on innovative cancer treatments.

✅ Japan's Ministry of Health approved Teserpaturev (G47Δ), a genetically engineered herpesvirus for malignant glioma - the first oncolytic viral therapy to receive conditional and fast-track approval, signifying regulatory support for advanced biologic cancer therapies in Japan.

✅ Noile-Immune Biotech received local government funding in July 2025 for next-generation CAR-T cell therapy targeting solid tumors, underscoring Japan's push toward innovative immunotherapy development and personalized cancer treatments.

Growth Drivers:

-Market expansion is driven by increasing prevalence of cancer, continued advancements in genetically engineered oncolytic viruses, and the country's strong emphasis on precision medicine and personalized cancer therapy.

-Japan is a pioneer in regulatory progress for oncolytic virus therapies, exemplified by early approval of Teserpaturev (G47Δ) for malignant glioma, demonstrating a high survival rate and fast-track access in clinical settings.

-Growing clinical trials and research collaborations between pharmaceutical companies and academic institutions support innovation in targeted cancer therapies.

-The market is further propelled by government funding, evolving regulatory frameworks, and integration of oncolytic virotherapy with immunotherapy and chemotherapy for enhanced efficacy.

-Japan's focus on treating difficult cancers like pancreatic and gastric cancers along with a rising elderly population augments demand for novel, less invasive treatment options.

-Key market players include both domestic biotechs and global pharmaceutical companies actively developing next-generation oncolytic viral therapies targeted to specific cancer markers.

Market Segmentation Analysis:

-By Virus Type

Herpesvirus (e.g., Teserpaturev G47Δ) is the most prominent virus type, with Japan pioneering its clinical use, particularly for malignant glioma.

Reovirus segment is expected to register the fastest CAGR (~30%) from 2025 to 2034, favored due to oncolytic and immunogenic properties.

Adenovirus, Vaccinia virus, and Other genetically engineered viruses form important segments with ongoing R&D and clinical trials.

-By Application

Solid Tumors are the primary application, especially in difficult-to-treat cancers such as pancreatic, gastric, and glioma cancers.

Hematologic Cancers and other cancer types represent growing areas, enhanced by combination therapies with immune checkpoint inhibitors.

Gene Therapy applications also exist, targeting cancer markers for precision treatment.

-By Mode of Administration

Intravenous delivery is gaining traction for systemic treatment, allowing better tumor penetration and immunomodulation.

Intratumoral injection remains common for direct virus application to localized tumors.

Other routes under exploration include intraperitoneal and aerosolized delivery.

-By End-User

Hospitals and Oncology Centers lead as primary end-users, supported by advanced clinical facilities and skilled healthcare professionals.

Research and Academic Institutions drive clinical trials, drug development, and translational research.

Biotechnology and Pharmaceutical Companies invest heavily in R&D and commercialization of oncolytic viral therapies.

Purchase this report before year-end and unlock an exclusive 30% discount: https://www.datamintelligence.com/buy-now-page?report=oncolytic-viral-therapy-market?ram (Purchase 2 or more Reports and get 50% Discount)

Japan Regional Insights:

The Japan oncolytic viral therapy market was valued around USD 0.2 billion in 2022 and is projected to reach USD 0.9 billion by 2030, exhibiting a strong CAGR of approximately 19.5% from 2024 to 2030. Growth is driven by rising cancer prevalence, increasing investments in advanced cancer immunotherapies, and rapid adoption of genetically engineered viruses targeting tumor cells. Japan's regulatory framework actively supports accelerated approvals, highlighted by the 2025 conditional approval of Teserpaturev (G47Δ) for malignant glioma, demonstrating one-year survival rates over 92%. Clinical adoption is growing across cancer types such as pancreatic, gastric, and glioma, with ongoing trials combining oncolytic viral therapy with immune checkpoint inhibitors enhancing treatment efficacy. Major research hubs like Tokyo, Kyoto, and Osaka lead innovation, supported by strong collaborations between pharma companies, academia, and government initiatives focused on precision medicine and gene therapy. This positions Japan as a key global player in oncolytic virotherapy, leveraging advanced biotechnology infrastructure and favorable regulations for continued market expansion.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/oncolytic-viral-therapy-market?ram

Competitive Landscape:

According to DataM Intelligence and related market research, the Japan Oncolytic Viral Therapy Market is poised for significant growth driven by rising cancer prevalence, increasing adoption of advanced immunotherapies, and a favorable regulatory framework encouraging innovation and approval of novel treatments.

Key Players:
Amgen, Inc. | Daiichi Sankyo Co., Ltd. | Lokon Pharma AB | Virogin Biotech Canada Ltd | KaliVir Immunotherapeutics, Inc. | Transgene SA | Vyriad, Inc. | Coastar Therapeutics Inc. | IconOVir Bio, Inc. | Calidi Biotherapeutics, Inc.

Key Highlights (Top 5 Key Players) for Japan Oncolytic Viral Therapy Market:

-Amgen, Inc. leads with significant global R&D investments and partnerships in Japan, focusing on oncolytic virus platforms combined with immune checkpoint inhibitors.

-Daiichi Sankyo Co., Ltd. is a major domestic player that achieved a milestone with the approval of DELYTACT (teserpaturev/G47∆) for malignant glioma, marking Japan's first oncolytic virus therapy, providing substantial clinical efficacy.

-Lokon Pharma AB collaborates on advancing virotherapy treatments targeting hard-to-treat solid tumors with innovative genetic engineering approaches.

-Virogin Biotech Canada Ltd emphasizes proprietary viral platforms optimized for cancer-specific targeting with ongoing trials registered in Japan.

-KaliVir Immunotherapeutics, Inc. develops novel oncolytic viral therapies with enhanced safety profiles and combinational treatment potential, actively engaging in clinical development within Japan.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription?ram

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.